News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

U.S. Patent Institutions Recognize The Patentability Of Institut Pasteur/Cellectis Early Inventions On Meganucleases


2/5/2014 10:07:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS), the genome engineering specialist, announced that, by the turn of the year, the US Patent and Trademark Office (USPTO) and the Courts of Appeal for the Federal Circuit (CAFC) independently recognized the merits of Cellectis and Institut Pasteur's early inventions on meganucleases.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES